

Index

a

- AADs. *See* aminoacetonitrile derivatives (AADs)
- ABZ-nitazoxanide 266
- ABZ-sulfone 260, 265, 266
- ABZ-sulfoxide 260, 265, 266, 272
- Acid fast bacilli (AFB) 329, 330
- acoziborole 129, 130
- acute fascioliasis 294
- adult flukes 295, 300
- adult worms 164, 166, 170–172, 175, 180, 190–192, 194–198, 200, 201, 206, 207, 254, 290, 293–296, 304
- African animal trypanosomiasis (AAT) 118, 119
- albendazole 2, 3, 9, 169, 171, 227–229, 257, 272, 275, 303
- Alpha-1-acid glycoprotein (AGP) 203, 212
- α -difluoromethylornithine 265
- 17- α -ethynylestradiol 298
- Alpinia nigra* 307, 311
- Alveolar echinococcosis (AE) 253
- benzimidazole treatments 257, 259–261
- clinical presentation 255, 257
- Aminoacetonitrile derivatives (AADs) 233, 234, 238
- patents 233
- amino-acetonitrile linker 234
- amino-malonitrile linker 234
- amino ozonids 267
- amino-pyrazole 147, 148
- amphotericin B 2, 3, 7, 140, 143, 144, 148, 260, 267, 272, 275
- anaerobic NADH-fumarate reductase system 275
- anthelmintic discovery
- medicinal chemistry approaches
- CODP 242–245
- intervet multicyclics 235, 238
- VACHT inhibitors 238, 240, 241
- new molecules, from patent literature 232–235
- anti-bacterial approach 169, 171
- antibacterial therapy vs. host directed therapy 354
- antibody-based therapeutics 67–69
- anticancer drugs 194
- anti-microbial properties 271
- metallo-organic ruthenium complexes 271
- proteasome inhibitor 271, 273
- anti-foodborne trematode drugs 304, 311
- anti-fungal agent 260
- anti-fungal compound amphotericin B desoxycholate (cAMB) 267
- anti-infective agents
- anti-echinococcal activities 267
- anti-malarial drugs 268
- extracellular protozoan parasites 267
- intracellular protozoan parasites 267
- anti-infective thiazolide 260
- anti-malarial compounds 267
- anti-malarial drugs 268
- antimalarials dihydroartemisinin 267
- anti-metacestodal activity 271

- antimicrobial susceptibility
 - testing 331
 - antimycobacterial drugs 329
 - antineoplastic properties 269
 - antiparasitic pharmaceuticals 230, 232
 - antischistosomes 190–192, 194–196, 204, 206–215, 195–200
 - anti-tuberculosis drug candidate 335
 - anti-tumor effects 270
 - artemisinin 267
 - artemisinin-derivatives 267
 - artemisinin peroxides 267
 - artesunate 190, 191, 267
 - arylmethylamino steroids (AASs) 212, 214
 - Ascaridia galli* 234, 235, 243
 - Ascaris lumbricoides* 227–229
 - ATP-binding cassette (ABC) 298
 - auxotrophies 275
 - ivermectin 170, 175, 336, 337
- b**
- BCX4430 29, 33, 68, 71, 72
 - benzimidazoles (BZD) 173, 174, 260, 266, 272, 275
 - benzimidazole chemotherapy 259
 - benzimidazole derivatives 303
 - benzimidazole monotherapy 228
 - benzimidazole 2, 3, 96, 97, 99, 101, 106, 107
 - β -tubulin genes 260, 266
 - Biarylalkyl carboxylic acids (BACAs) 190, 206–212, 214
 - Biarylethylamides (BAEAs) 233, 234
 - bi-cyclic spiro-piperidine urea 241
 - bilateral symmetry 290
 - Bilharzid[®] 297
 - Biltricid[®] 297
 - biochemical assays 26–28, 307, 308, 310
 - bithionol 304
 - blood-streaked pneumonia-like sputum 295
 - boron derived benzimidazoles 175
 - bortezomib 273
 - bortezomib-mediated inhibition 271
- Brugia*
- B. malayi* 172–175, 177, 268
 - B. patei* 268
- Buruli ulcer (BU) 327
- clinical studies 336, 338
 - results 336, 338
 - therapeutic approach 338
 - treatment, BU lesions 338
- compound screening 336
- current treatments
- antibiotic treatment, for pregnant women 328
 - antibiotic treatment, in Australia 328
 - standard antibiotic treatment 328
- diagnostics 329–330
- discovery models
- in vitro test formats 330–331
 - in vivo test formats 331–332
- future directions 338–339
- preclinical profiling 332
- preclinical profiling, antibiotics 332
- repurposing, tuberculosis drug candidates 332, 335–336
- unmet needs 329
- c**
- Caenorhabditis elegans* 189, 240, 302
 - Caenorhabditis elegans* model 302
 - carboxamides 129, 212, 233–235
 - carvacrol 274
 - celgosivir 24
 - cell-based assays, Ebola virus disease (EVD) 54
 - cell-based ZIKV assays 25
 - cerariae 293
 - cercariae 290, 291, 293–296
 - cerebral cholesterosis 273
 - cerebral invasion 299
 - cerebral paragonimiasis 299
 - cestodes 261, 268, 273, 275, 297
 - cetrimide 272
 - Chagas disease (CD)
 - bioluminescent imaging (BLI) mouse model 97
 - compound selection 98

- and identification of potential hits/starting points 98
 - mechanism 106–107
 - model 96–107
 - overview 95–96
 - site of action 103–106
 - sterile cure 96–107
 - in vitro* assays to guide structural optimisation 101–103
 - Chenodeoxycholic acid (CDCA) 273
 - Chinese Food and Drug Administration 228
 - 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio) benzimidazole 299
 - chloroform 297, 302, 305, 308
 - chloroquine 24, 265, 304
 - Cholangiocarcinoma (CCA) 293, 294, 299
 - cholangitis 293, 294
 - cholecystitis 293, 294
 - cholelithiasis 294
 - chronic clonorchiasis 293
 - chronic fascioliasis 294
 - chronic mycobacterial infection 349
 - chronic opisthorchiasis 293
 - cimetidine 298
 - clarithromycin 268, 269, 328, 329, 332–334, 336–338, 352, 354, 356
 - clofazimine 2, 3, 192, 193, 334, 336, 350–354, 356, 357
 - clonorchiasis 293, 298, 301
 - Clonorchis sinensis* 290, 291, 293, 294, 303, 307
 - 2'-C-methylated nucleosides 32
 - Cocos nucifera* 305, 308, 311
 - combination chemotherapy 228, 229
 - Commiphora molmol* 307, 309, 311
 - Contrast enhanced ultrasound (CEUS) 257
 - Cooperia curticei* 234
 - corallopyronin A 178–180
 - cotrimoxazole 336
 - Crassostrea gigas* 296
 - crustacea 291, 294
 - Cutaneous leishmaniasis (CL) 141–143
 - cyclic AMP (cAMP) 127
 - 1,3-cyclohexanedioic acid 235
 - 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 297
 - Cyclooctadepsipeptides (CODP) 176–177, 242–245
 - cyclosporin 272, 273, 352, 357
 - Cyp450
 - enzyme 266
 - inhibitors 298
 - cyst dimension 255
 - Cystic echinococcosis (CE) 253
 - benzimidazole treatments 257, 259–261
 - clinical presentation 255–257
 - cytostatic drugs 270
 - cytotoxicity 6, 25, 54, 127, 130, 175, 195–197, 199, 261, 267, 268, 271
 - cytotoxic properties 269
- d**
- Diethylcarbamazine (DEC) 167–171
 - digenean trematodes 290
 - Dihydroorotate dehydrogenase (DHODH) 24
 - dimethylformamide 302
 - dimethylsulfoxide 297
 - di-N-aryl-diguanidino compounds 267
 - diphenylhydramine 298
 - diplostomiasis 295
 - diplostomidae 295
 - direct acting antibacterial therapy 350–355
 - direct-acting antivirals 28, 67–74
 - direct acting approach 169–170
 - direct antiviral agents 24–25
 - Dirofilaria immitis* 234, 235, 238
 - Disability adjusted life years (DALYs) 165, 227, 289, 293, 295
 - disk-diffusion testing 331
 - Distocide® 297
 - doxorubicin 269

- Droncit® 297
- Drosophila melanogaster* 238
- drug discovery efficiency 3–7
- drug discovery strategies 1–10, 289
- drug level-monitoring 260
- drug repurposing 95, 127, 128, 148, 190–194, 213, 264–274, 312, 332
- treating AE
- anti-cancer drugs 269–271
 - anti-infective agents 265–269
- treating CE 272–274
- Drugs for neglected diseases initiative (DNDi) 9, 10, 98, 108, 123, 125, 126, 129, 144, 145, 147–150, 153, 173, 177, 188, 229, 244, 338
- e**
- Ebola virus disease (EVD)
- animal models for efficacy testing 54–57
 - cell-based assays 54
 - challenges and innovations 50–52
 - diagnostic tests 50
 - direct-acting antivirals 67–74
 - genome structure, components, and replication cycle 52
 - host targets 67
 - kinases and phosphatases 60
 - non-proteolytic endosomal targets 63–65
 - nucleic acid inhibitors 70–71
 - nucleoside analogs/polymerase inhibitors 71–74
 - overview of 49–50
 - priming host immune responses 65–67
 - protein folding and processing 60–63
 - S-adenosyl-homocysteine hydrolase inhibitors 57–60
 - surveillance and research diagnostic tools 51
 - therapeutic strategies
 - host-directed antivirals 57
 - viral protein interactions 69–70
- Echinococcosis 253
- in vitro and in vivo models 261, 263, 264
- Echinococcus* 253
- E. canadensis* 253
 - E. equinus* 253
 - E. felidis* 253
 - E. granulosus sensu lato* 253
 - E. granulosus sensu stricto* 253
 - E. intermedius* 253
 - E. multilocularis* genome 260
 - E. multilocularis* metacestodes 256, 260, 261, 264–271
 - E. oligarthrus* 253
 - E. ortleppi* 253
 - E. vogeli* 253
- Echinococcus granulosus* 253, 254, 261, 267
- biological feature 254–255
 - metacestodes 255
- Echinococcus multilocularis* 253, 254, 257, 263, 269
- biological feature 254–255
 - metacestodes 255
- Echinostomatidae 295
- echinostomes 295, 301
- echinostomiasis 295, 303
- echinostomes 295, 301
 - symptoms 295
- eflornithine 2, 3, 6, 9, 118–124, 128
- embryonated eggs 293, 296
- embryonation 291, 294
- emodepside 176, 177, 232, 242, 244
- Enzyme linked immunosorbent assay (ELISA) 51, 54, 125, 169, 257
- epoxy-activated Sepharose® 268
- ethacrynic acid 271
- ethyl-N-dimethyl ether 272
- eye lesions 163, 166–168
- f**
- Fasciola*
- F. gigantica* 294, 304, 306, 307, 309
 - F. hepatica* 290, 291, 294, 300, 301, 304–306, 309–311
- fascioliasis 2, 293, 294, 303, 304
- fasciolopsiasis 296

- Fasciolopsis* 303
E. buski 292, 296, 301, 304, 307, 308, 311
 Favipiravir (T-705) 63, 68, 71, 72
 Federal Drug Administration (FDA)
 7, 9, 30, 32, 58, 59, 63, 65, 68,
 70–72, 96, 140, 142, 143, 189,
 202, 203, 270, 271
 fenbendazole 9, 260, 266, 272
 fexinidazole 9, 97, 99, 101, 105,
 129–131
 F18-fluorodeoxyglucose-positron
 emission tomography
 (FDG-PET) 257
 Fite-Faraco staining 353
 flavin monooxygenase 300
Flemingia vestita 307, 311
 Flubendazole (FLBZ) 9, 173–174,
 272
 Foodborne trematode (FBT) infections
 289
 adult worms 290
 diagnosis 290
 drugs used against
 praziquantel (PZQ) 296–299
 TBDD 301–303
 TCBZ 299–301
 epidemiology 292–293
 global impact 292–293
 intestinal
 diplostomiasis 295
 echinostomiasis 295
 fasciolopsiasis 296
 gymnophalloidiasis 296
 heterophyasis 296
 life cycle of 292
 liver
 clonorchiasis 293–294
 fascioliasis 294
 opisthorchiasis 293–294
 lung 294–295
 morphology and biology of 290–292
 naphthoquinone plumbagin 311
 trematocidal compounds 310
 trematocidal drug discovery 304
 fork-tailed cercariae 295
 free-swimming miracidia 294
- g**
 Galidesivir (BCX4430) 68, 71, 72
 γ -carbolines 240, 241
 genistein 58, 60, 61, 269, 307, 311
 glibenclamide 273, 274
 Glutathione-S-transferase (GST) 271
Gracinia mangostana 306, 308–310
 Guillain-Barré syndrome (GBS) 19, 21
Gymnophalloides seoi 296
 gymnophalloidiasis 296, 299
 gynecomastia 273
- h**
Haemonchus contortus 234, 235, 238,
 241–244
Hagenia abyssinica 306–308, 310
 halogenated benzimidazole 299
 η 6-areneruthenium 271
Heligmosomoides polygyrus 234
Heliothis virescens (tobacco budworm)
 238
 hemolymphatic stage 118
 heterocyclic pyrazinoisoquinoline
 derivative praziquantel 259
 heterophyasis 296
Heterophyes heterophyes 296, 311
 Heterophyidae 291, 296
 hexachloro-para-xylol 304
 hookworm infections 227–229, 274
 host cell toxicity 101, 102, 262
 host-directed antivirals 57, 67
 host directed therapy 354, 355, 358
 host targeting agents 24, 36
 Human African trypanosomiasis
 (HAT) 1
 biological activity and cell penetration
 126
 chemotherapeutics for 119
 diagnostics for 123–125
 distribution of 117
 Eflornithine 122
 etiology and epidemiology 115–119
 GNF6702 131
 GNF5343 to GNF6702 131
 immunochromatographic lateral flow
 device 125
 medicinal chemistry 125–129

- Human African trypanosomiasis (HAT) (*contd.*)
- melarsoprol 122
 - neglected tropical diseases (NTDs) 115
 - overview 115
 - pentamidine 121
 - suramin 119
 - target product profile for 126
 - treatments for 119–123
- human aldose-reductase (hAR) 196, 197, 207, 208
- human kinase inhibitors 148, 202–205
- hydroxydaunorubicin 269
- i**
- imidazopyridine carboxamide (IPA) compounds 335, 336
- immune reconstitution inflammatory syndrome 338
- immunochromatographic lateral flow device 125
- immunodiagnosis 257
- immunodiagnostic tests and PCR 169
- immunomodulation 23, 265
- immunosuppressant drug cyclosporin A 272
- Indirect immunofluorescence assays (IFAs) 51
- innovative therapeutic strategies 355, 358
- Insertion sequence (IS) 329
- International Agency of Research on Cancer (IARC) 294
- intestinal FBT infections
- diplostomiasis 295
 - echinostomiasis 295
 - fasciolopsiasis 296
 - gymnophalloidiasis 296
 - heterophyiasis 296
- in vivo efficacy models 173
- ionophore monensin 272
- isatin 269
- isoflavonoids 269
- isoflavonoid genistein 269
- isoxazolines 238
- ivermectin 2, 3, 9, 165, 170–171, 192, 213, 228–230, 265, 272, 337
- j**
- Juglans regia* 274
- juvenile worms 190, 292, 294, 296
- k**
- 7-keto-semperviroil 306, 311
- kinases 2, 8, 10, 33, 58, 60, 61, 127, 128, 148, 150–152, 190, 194, 202–206, 269, 270, 273, 274, 298
- l**
- Leishmania* 99, 103, 127, 139–143, 145, 150–152, 267
- Leishmania* casein kinase 1.2 (LmCK1.2) 152
- Leishmaniases
- phenotypic screening approaches 144–150
 - phenotypic screening approach vs target-based approach 144
 - in silico computational approach 152–153
 - target-based approaches 150–152
 - target product profile for 145
- leprosy
- clinical staging 351
 - direct acting antibacterial therapy 350, 353, 355
 - drugs 356
 - innovative therapeutic strategies 355–358
 - mycobacterial species 349
 - unmet medical needs 349–350
- leukotriene inhibitors 354, 358
- levamisole 227, 228, 272, 302, 303
- liver FBT infections
- clonorchiasis 293–294
 - opisthorchiasis 293–294
- liver trematodes 304, 311
- low-density lipoproteins 119, 120
- luciferase-catalyzed reaction 331
- lung FBT infections 294–295
- Lycium chinense* 306, 311

- lymphatic filariasis 1, 2, 165, 170, 171, 173, 175, 177, 178, 180, 228, 229
- m**
- macrocyclic lactones 9, 175–178, 230, 336
- malate dismutation pathway 260, 275
- mangostin 306, 308–311
- mangostin diacetate 309, 311
- MAPK pathway 202
- Mass drug administration (MDA) 1, 165, 187
- maximum plasma concentration (C_{\max}) 103
- Mazzotti test 168
- mebendazole 9, 227, 228, 257, 303
- Mechanism of action (MOA) 3–7, 25, 57, 64, 65, 74, 98, 106–107, 120–123, 126, 170, 188, 191, 238, 298, 300, 302, 310, 311
- medicinal chemistry approaches
 CODP 242–245
 intervet multicyclics 235, 238
 VAcHT inhibitors 238, 240, 241
- Medicines for Malaria Venture (MMV) 188, 268
- mefloquine 192, 265, 267, 268, 275
- mefloquine enantiomers 267
- mefloquine-sepharose matrices 268
- melarsoprol 2, 119–124, 126
- Mentha*
M. piperita 274, 305
M. pulegium 274
- Meriones unguiculatus* 173, 174, 269
- metabolite p-(1-dimethylamino ethylimino) aniline (dADT) 302
- metabolites 3, 25, 28, 74, 130, 169, 173, 176, 179, 198, 213, 242, 255, 260, 265, 266, 270, 272, 275, 298, 300–302
- metacercaria 290, 295
- metacercariae 292, 294, 296
- metacercariae excyst 292, 294, 296
- metacestodes 254–256, 259–275
- Metagonimus yokogawai* 296
- metallo-drugs 271
- metallo-organic ruthenium complexes 271
- metastasis formation 255, 274
- 2-methoxyestradiol (2-ME) 270
- methylation 33, 34, 57
- microtriches 255, 256, 260
- milbemycins 175–176
- miltefosine 2, 3, 140, 142–144, 147–149, 265
- Minimum effective dose (MED) 234
- Minimum inhibitory concentrations (MICs) 103, 330
- Minimum lethal dose (MLD) 234
- miracidia 291, 293–296
- miracidium 290, 291, 295
- Mirazid[®] 307, 309, 311
- Mitogen-activated protein kinase (MAPK) 202, 270
- mongolian gerbils 234
- mono-spiropiperidine ureas 241
- monotherapy 32, 96, 121, 123, 128, 141, 228, 266, 329, 333, 350, 355, 356
- moxidectin 9, 175, 176, 194, 228, 229, 337
- moxifloxacin 328, 329, 332–334, 336, 337, 354, 356
- MTase inhibitors 30–34
- Mucosal leishmaniasis (ML) 142–144
- multicyclic patents 233
- Multi-drug therapy (MDT) 349, 350, 352, 353, 355, 357, 358
- Mycobacterium*
M. leprae 349, 350, 353–356, 358
M. lepromatosis 349, 350, 354
M. tuberculosis 103, 105, 330, 332, 335–337
M. ulcerans 327–338
- mycolactone 327, 328
- Myrrh 307, 311
- Myrtus communis L.* 274
- n**
- 1,4-naphthoquinone ethers 195
- Nectaroscordum tripedale L.* 274

- Neglected tropical diseases (NTDs)
 1, 338, 349
 critical components for 7, 8
 drug discovery efficiency 3
 drug discovery strategies for 3, 6
 mechanisms 1–3
 PDD vs TDD for 6–7
 repurposing knowledge mechanisms
 and therapeutics 9–10
- Neodiplostomum seoulensis* 295
- netobimin 272
- neuromuscular vesicular acetylcholine
 238
- Newly excysted juveniles (NEJs)
 304–307, 311
- nicosamide 2, 192, 193, 268
- Nifurtimox-eflornithine combination
 therapy (NECT) 119, 121, 123,
 128, 131
- Nippostrongylus brasiliensis* 234
- nitinoxazide 304
- nitazoxanide 192, 232, 260, 265, 266,
 271, 272, 275, 354, 356
- nitazoxanide monotherapy 266
- NITD008 29, 31, 33
- nitroimidazole 97, 130, 149, 150
- N,N-Di-[4-(1-dimethylaminoethy-
 limine)phenyl]-1,4-xylene imine
 302
- nocodazole 272
- nodding syndrome 167
- nodules 142, 163, 164, 166, 168, 169,
 172, 173, 328, 338, 351
- nodulectomy 172
- non-proteolytic endosomal targets
 63–65
- NS2B-NS3 protease 27, 35
- NS3 helicase 26–28, 34, 35
- NS5 MTase and polymerase 26–27
- NS3 protease and helicase inhibitors
 34–36
- NS5 RdRp and MTase inhibitors
 30–34
- nucleic acid inhibitors 70–71
- nucleoside analogs/polymerase
 inhibitors 71–74
- Nucleotide triphosphate (NTP) 28
- O**
- Oesophagostomum dentatum* 234,
 235
- Onchocerciasis drug discovery
 albendazole 171
 anti-bacterial approach 171
 benzimidazole (BZD) 173–175
 boron derived benzimidazoles 175
 clinical diagnosis 168
 clinical manifestation 166–167
 corallopyronin A 178–180
 cyclooctadepsipeptides 176–177
 diethylcarbamazine 170
 direct acting approach 169–170
 epidemiology 165
 eye lesions 166–167
 flubendazole (FLBZ) 173–174
 immunodiagnostic tests and PCR
 169
 ivermectin 170–171
 life cycle of 164–165
 mazzotti test 168
 milbemycins 175–176
 nodding syndrome 167
 nodules 166
 nodulectomy 172
 parasitological diagnosis 168
 primary in vitro assays 172
 pyrazolopyridine 180
 skin lesions 166
 suramin 171
 tetracycline derivatives 171–172
 tylosin A 177–178
 ultrasonography 168
 UMF-078 174–175
 in vivo efficacy models 173
- opisthorchiasis 293, 298, 301,
 303
- Opisthorchis*
O. felineus 293, 294
O. viverrini 268, 293, 294, 299, 302,
 303, 309, 311
- Opisthorchis* spp. 291, 293
- Opistorchiidae 304
- organic solvents 297
- organometallics 190, 199–200
- Origanum vulgare* 274, 275

- Ornithine decarboxylase (ODC) 2, 6,
120, 123
inhibitor 6
- Oxantel 228, 229
- oxantel pamoate 228, 229
- oxfendazole 9, 260, 266, 272
- oysters 296
- P**
- paradoxical reactions 338
- paragonimiasis 293–295, 298–301
- paragonimiasis 294, 295
causes 295
pathological features 295
zoonotic disease 294
- Paragonimus* 291, 294, 303, 304
- patent landscape 2005–2017 232, 233
- PDD, vs TDD 6–7
- Pentamidine 2, 3, 119–122, 124, 141,
267, 272
- 1,5-pentanedioic acid 235
- peptidyltransferase 268
- periductal fibrosis 293
- Pestalotiopsis* sp. 274
- pharmacodynamic effects 106
- Pharmacokinetic-pharmacodynamic
(PK/PD) 103
- phosphatases and kinases 60
- Phosphoglucose isomerase
(PGI) 261, 262, 264,
266–268
- piperidine moiety 241
- piperitone oxide 274
- Plasmodium* 267, 271
P. falciparum 202, 213, 268
- Plumbago* spp. 307, 311
- Plutella xylostella* (diamond back moth)
240
- polycystic echinococcosis 253
- polyisohexylcyanoacrylate nanoparticles
269
- Polymerase chain reaction (PCR) 20,
140
- praziquantel (PZQ) 2, 3, 187–189, 232,
242, 259, 265, 272, 296–299
- Prazitel® 297
- primary in vitro assays 172
- priming host immune responses
65–67
- propargylic alcohols 265, 269
- proteasome inhibitor 271, 273
- protein folding and processing 60–63
- protein kinases 60, 150, 194, 202, 270,
274, 298
- proteolytic enzymes 265
- protoscolecemes 254, 255, 259, 263, 264,
266, 269, 270, 272–274
- pyrantel 228
- pyrazolopyridine 180
- pyrazolopyrimidines 148, 149
- pyridinyl imidazoles 270
- Q**
- Quantitative reverse transcription
polymerase chain reactions
(qRT-PCR) 50, 51, 73
- R**
- rapalogs rapamycin 273
- rapamycin 273
- rare immune-mediated reactions 257
- respiratory cytochrome 335
- Respiratory syncytial virus (RSV)
infection 30, 31
- ribavirin and T-705
(favipiravir) 30–32
- ricobendazole 260
- Ridley-Jopling system 351
- rifampicin (RIF) 2, 265, 328
- RNA-dependent RNA polymerase
(RdRp) 23, 26, 71
- RNA interference (RNAi) 127, 189,
202, 263, 298
- S**
- “sac-like” ciliated larva 291
- S-adenosyl-homocysteine hydrolase
inhibitors 57, 60
- salicylanilide-derivative 268
- salicyl moiety 266
- Schistosoma*
S. japonicum 189–191, 196–198,
200, 201, 206, 267

- Schistosoma mansoni*
 histone deacetylase 8 (*SmHDAC8*)-
 ligand complex 195
 3-hydroxy-3-methylglutaryl
 coenzyme A reductase
 (*Sm HMGR*) 192
 polo-like kinase 1 (*SmPLK1*) 203
 thioredoxin glutathione reductase
 (*SmTGR*) 195
- Schistosoma* spp. 297, 300
- schistosomiasis 254, 297, 311
 arylmethylamino steroids (AASs)
 212–213
 biarylalkyl carboxylic acids (BACAs)
 206–212
 drug development pipeline 213–215
 drug repurposing for 190–194
 natural products 200–202
 neglected tropical disease (NTD)
 187–189
 organometallics 199–200
 phenotypic approaches 196–199
 potential drug targets 202–206
 strategies, tools and target product
 profile (TPP) 189–190
 structure-based drug design for
 195–196
 for treatment 187–189
- Semisulcoospira* 294
- sense single-stranded RNA (ssRNA)
 21–23
- serine/threonine kinases 270
- silico* approach 152, 268
- skin lesions 140, 166, 168, 327, 328,
 351
- small fox tapeworm 253
- sodium arsenite 273
- Soil transmitted helminthiasis (STH)
 anthelmintic discovery
 medicinal chemistry approaches
 235–238
 new molecules, from patent
 literature 232–235
 anthelmintic research and
 development, animal health
 229–230, 232
 therapies and needs 227–229
- Sorafenib 270
- spiroindolines 238, 240, 241
- sporocysts 290, 291, 293–296
- sporotrichoid spread 141
- Streptomycin (STR) 2, 328, 329,
 331–334, 336–338
- Structure activity relationship (SAR)
 119, 127, 152, 176, 179, 196–198,
 237, 243, 261, 302, 336
- suramin 1, 2, 119–121, 171, 272
- symptomatology 296
- syngenta spiroindolines 238, 240
- synthetic and semi-synthetic
 artemisinins 311
- t**
- Taenia*
T. crassiceps 273
T. solium 261, 273
- tamoxifen 59, 64, 65, 269, 273
- Target product profile (TPP) 8, 107,
 125, 126, 139, 145, 170, 189–190,
 213
- T-cell immunoglobulin and mucin
 domain (TIM) 21
- tegument 205–208, 212, 213, 255,
 256, 260, 290, 306, 307, 309,
 310
- tegumental microtriches 260
- Terephthaldehyde (TPAL) 302
- Terephthalic acid (TPAC) 302
- tetracycline derivatives 171–172
- thermosensitivity 338
- thiazole moiety 266
- thiazolide nitazoxanide 272
- thiophene-diguanidino derivatives
 267
- thymol 266, 272, 274, 275
- Thymus vulgaris* 274, 275, 305
- Toxoplasma* 271
- transcriptome 261, 263
- Transmission electron microscopy
 (TEM) 256, 267, 268, 273, 274,
 307, 310
- trematocidal drug 304, 310, 311
- trematoda 289

- Tribendimidine (TBDD) 228, 229, 297, 301–303, 312
- Trichostrongylus colubriformis* 234, 235, 238, 241–243
- Trichuris trichiura* 227–229
- Trichuris trichiura* infections 227–229
- Triclabendazole (TCBZ) 2, 297, 299–301
- Trypanosoma brucei* 115
 blood-stream form 128
 life cycle of 116
 mechanism of 127
- Trypanosoma cruzi*
 antibodies 96
 complex pathology of 95
 CYP51 inhibitors 101
 metabolic plasticity of 107
- trypanosomatid 150, 271
- trypanosomiasis 118, 125, 254
- tub-2 isoform 260
- tubulin dimer 260
- Tylosin A 177, 178
- tyrosine kinases 60, 128, 203, 269, 270
- U**
- ubiquitinated proteins 271
- unicystic echinococcosis 253
- urticaria 168, 257
- V**
- vero cells 25, 32, 33, 271
- Vesicular acetylcholine transporter (VACHT) inhibitors 238–241, 245
- Virus-like particles (VLPs) 54, 59, 69
- Visceral leishmaniasis (VL) 99, 101, 139–141
- W**
- Whole genome sequencing (WGS) 51, 106
- World Health Organization (WHO) 17, 20, 115, 117, 165, 227, 304, 328, 338, 349, 352
- Worm burden reductions (WBR) 190, 303, 309–311
- X**
- xylool derivative 304
- Z**
- zafirlukast 354, 358
- Zika virus (ZIKV) 25
 animal models for evaluating in vivo efficacy 28–30
 anti-ZIKV drug discovery, in vitro tools for
 biochemical assays and tools 26–28
 cell-based ZIKV assays 25
 NS2B-NS3 protease 27
 NS3 helicase 27–28
 NS5 MTase and polymerase 26–27
- BCX4430 33
- 2'-C-methylated nucleosides 32
- from dengue antiviral research 23–25
 direct antiviral agents 24–25
 host targeting agents 24
 detection, clinical presentation, and medical need 20–21
 history and epidemiology 17–20
 MTase inhibitors 33–34
 NITD008 33
 NS3 protease and helicase inhibitors 34–36
 NS5 RdRp and MTase inhibitors 30–34
 other classes of small molecules against 36–37
 outbreak in Oceania 19
 replication cycle 21–23
 ribavirin and T-705 (favipiravir) 30–32
 zymography 271

